Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

Table 3

EDSS score at 2 years in patients with optimal (0 relapse) or suboptimal responses (≥1 relapses) at 1 year—ITT population.

	Optimal	Suboptimal	𝑃 value^a
EDSS score
n	637	218
Mean (SD)	2.093 (1.283)	3.016 (1.605)
Median	2.0	3.0	<0.0001
Range	0, 6.5	0, 8.0

^a: 𝑃 value is from Wilcoxon rank sum test.